On the evening of January 6, Chongqing Zhifei Biological Products announced that it had recently learned that its wholly-owned subsidiary Anhui Zhifei Longkema Biological Pharmaceutical Co., Ltd. (referred to as 'Zhifei Longkema') has developed a trivalent influenza virus split vaccine (ZFA02 adjuvant) (referred to as 'adjuvanted trivalent influenza vaccine'), which has received the national drug administration's acceptance notice for clinical trial applications. If no adverse or questionable opinions are received from the drug review center within 60 days from the date of acceptance, Zhifei Longkema can conduct clinical trials according to the submitted plan.